BACH1 and oxygen levels in triple‑negative breast tumors
Regulation of Tumor Oxygenation by BACH1 in Breast Cancer
This work looks at whether changing the activity of a protein called BACH1 can reduce low‑oxygen areas inside triple‑negative breast tumors and make treatments like radiation work better for people with TNBC.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11167658 on NIH RePORTER |
What this research studies
Researchers will use lab-grown triple‑negative breast cancer cells, animal tumor models, and analysis of human tumor samples to study how BACH1 controls tumor oxygen levels and blood vessel leakiness. They will manipulate BACH1 levels with molecular tools and measure blood flow, oxygenation, and antioxidant responses in tumors. The team will also test whether lowering BACH1 makes radiation more effective against TNBC tumors in model systems. Findings could point to ways to change the tumor environment to help standard therapies work better.
Who could benefit from this research
Good fit: People with triple‑negative breast cancer, especially those undergoing surgery or radiation who are willing to donate tumor tissue or participate in related clinical sampling, would be the most relevant candidates.
Not a fit: Patients with non‑triple‑negative breast cancers or those not eligible for tissue donation or radiation‑based approaches are unlikely to receive direct benefit from this work.
Why it matters
Potential benefit: If successful, this could lead to new approaches that reduce tumor hypoxia and increase the effectiveness of radiation and other treatments for triple‑negative breast cancer patients.
How similar studies have performed: Previous research shows that improving tumor oxygenation can increase treatment response, but targeting BACH1 specifically is a newer, early‑stage approach with limited prior clinical testing.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Rosner, Marsha R — University of Chicago
- Study coordinator: Rosner, Marsha R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.